Last reviewed · How we verify

Auris Medical AG — Portfolio Competitive Intelligence Brief

Auris Medical AG pipeline: 1 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Intranasal Drug Intranasal Drug marketed
AM-101 AM-101 phase 3 NMDA receptor antagonist NMDA receptor Otolaryngology / Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ajou University School of Medicine · 1 shared drug class
  2. Alameda Health System · 1 shared drug class
  3. American University of Beirut Medical Center · 1 shared drug class
  4. Asker & Baerum Hospital · 1 shared drug class
  5. AstraZeneca · 1 shared drug class
  6. Beijing Tiantan Hospital · 1 shared drug class
  7. Celon Pharma SA · 1 shared drug class
  8. Acacia Pharma Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Auris Medical AG:

Cite this brief

Drug Landscape (2026). Auris Medical AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/auris-medical-ag. Accessed 2026-05-17.

Related